MACROCYCLIC COMPOUNDS FOR THE TREATMENT OF PROLIFERATIVE DISEASES

WIPO Patent Application WO/2015/050989

A3

The compounds and salts of the present invention inhibit kinases, especially the anaplastic lymphoma kinase (ALK) and the HGF receptor tyrosine kinase (RTK) c-Met, and are useful for treating or ameliorating abnormal cell proliferative disorders, such as cancer.

JPS53133637	PHARMACEUTICAL COMPOSITION
JP2003501353	[Title of Invention] Crystals of (2-benzhydryl-1-azabicyclo [2.2.2] octo-3-yl)-(5-isopropyl-2-methoxybenzyl) -amine citrate as an NK-1 receptor antagonist. Polymorph
WO/1999/063993	MULTIVALENT AGONISTS, PARTIAL AGONISTS, INVERSE AGONISTS AND ANTAGONISTS OF THE D¿1? RECEPTORS

SONG YUNTAO (US)
BRIDGES ALEXANDER JAMES (US)

PCT/US2014/058623

September 24, 2015

October 01, 2014

Click for automatic bibliography generation  

CS THERAPEUTICS INC (US)

A61K31/435; C07D491/18; A61P35/00; C07D491/22; C07D495/18; C07D495/22; C07D497/18; C07D498/18; C07D498/22; C07D515/18; C07D521/00

US20130252961A1	2013-09-26
US20110152310A1	2011-06-23

TED W. JOHNSON ET AL: "Discovery of (10 R )-7-Amino-12-fluoro-2,10,16-trimethyl-15-oxo-10,15,16,17-tetrahydro- 2H -8,4-(metheno)pyrazolo[4,3- h ][2,5,11]-benzoxadiazacyclotetradecine-3-carbonitrile (PF-06463922), a Macrocyclic Inhibitor of Anaplastic Lymphoma Kinase (ALK) and c-ros Oncogene 1 (ROS1) with Preclinical Brain", JOURNAL OF MEDICINAL CHEMISTRY, vol. 57, no. 11, 12 June 2014 (2014-06-12), pages 4720 - 4744, XP055136233, ISSN: 0022-2623, DOI: 10.1021/jm500261q

NEY, Joshua, E. et al. (524 South Main Street Suite 20, Ann Arbor MI, US)

View/Download PDF      PDF Help

Previous Patent: BATTERY OVERMOLDING

Next Patent: COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF THE LECT2 GENE